There would appear to be a link between MA and JAK2 mutant allele burden implying that the allelic burden is not only influencing the clinical phenotype, and disease evolution, but also the overall methylation landscape of the MPN cells (55). This evidence concerns the gene JAK2 and myeloproliferative neoplasm.